Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

Parkinson’s Disease Clinical Trial to Launch in Japan | iPS Cell Trial

August 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.

Existing iPS Cell Trials

This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]

Dr. Paul Wotton on the Future of Cynata Therapeutics’ Novel iPSC-Derived MSCs

July 10, 2018 By Cade Hildreth, Founder & President Leave a Comment

This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016. Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. [Read more…]

Eppendorf introduces first ready-to-use, synthetic cell cultureware for iPSC and MSC stem cells

July 3, 2018 By Cade Hildreth, Founder & President Leave a Comment

Hamburg, June 2018 – Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has experienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell applications including regenerative medicine. [Read more…]

Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD

June 27, 2018 By Cade Hildreth, Founder & President Leave a Comment

MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]

FUJIFILM CDI Partners with UC Irvine to Commercialize iPSC-derived Microglia & Media

June 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

FUJIFILM Cellular Dynamics licenses University of California – Irvine’s technologies for derivation of microglia

MADISON, Wis., June 6, 2018 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSCs, announced today that it has entered into an exclusive patent license agreement with the University of California – Irvine (UCI) through its offices at UCI Applied Innovation to license and commercialize UCI’s technologies for derivation of microglia in the commercial research field and also a non-exclusive patent license agreement to commercialize microglia media formulation. [Read more…]